Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Viking Bolsters MASH Case With 52-Week Histology Data

Jun 04 2024

• By Joseph Haas

SC2008_Fatty Liver_274834199_1200.jpg — Viking's 52-week biopsy data bolster case for VK2809 in MASH

Related Content

Viking’s Phase IIb NASH Data Provide Across-The-Board Success

May 16 2023

AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH

Nov 17 2023

A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian

Apr 12 2024

Viking’s Oral Weight-Loss Drug Shows Early Efficacy/Safety Promise

Mar 26 2024

Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration

Mar 14 2024

Related Companies

Viking Therapeutics, Inc.

Madrigal Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window